“Move your money by early 2022,” Wall Street legend warns
A new form of technology will cause a massive shift in the wealth divide in 2022. Do you own the stocks that will be affected?
Details here…

INS Insider Trading (Instem)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £20,625
Insider Selling (Last 12 Months): GBX 0

Instem Insider Trading History Chart

This chart shows the insider buying and selling history at Instem by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Instem Share Price & Price History

Current Price: GBX 856
Price Change: Price Decrease of -11.5 (-1.33%)
As of 01/21/2022 01:00 AM ET

This chart shows the closing price history over time for INS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Apple Could Be Days Away From Shocking The World
The "Black Box" Device Bringing the Age of the Smartphone to an End.
Learn More

Instem Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/11/2021Nigel GoldsmithInsiderBuy2,500GBX 825£20,625
7/17/2020Phil ReasonInsiderSell142,000GBX 435£617,700
6/26/2020David GareInsiderSell40,000GBX 435£174,000
5/29/2019Michael McGounInsiderSell6,786GBX 340£23,072.40
5/21/2019Michael McGounInsiderSell30,000GBX 348£104,400
2/20/2019Phil ReasonInsiderSell73,750GBX 295£217,562.50
See Full Table
Insider Buying at Instem?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Instem and related companies.

SEC Filings (Institutional Ownership Changes) for Instem (LON:INS)

Instem logo
Instem plc, together with its subsidiaries, provides information technology applications to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource EDC system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Logbook, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a Windows-based system for organizations and universities in non-clinical evaluation studies. In addition, the company provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; SEND Explorer, a web-based application with optional data warehousing capabilities; SENDTrial, a Web based solution that can be accessed through a subscription; and standard for exchange of nonclinical data solutions. Further, it provides Sorcerer Colony Counter for automatic plate counter; anonymization, cloud, validation, and safety assessment and regulatory information management software services; and software solutions to extract intelligence from research and development related healthcare data. Additionally, the company develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.
Read More on Instem

Today's Range

Now: GBX 856
Low: 856
High: 860.79

50 Day Range

MA: GBX 840.01
Low: 770.51
High: 900

52 Week Range

Now: GBX 856
Low: 490
High: 910

Volume

8,516 shs

Average Volume

43,251 shs

Market Capitalization

£189.95 million

P/E Ratio

109.74

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Instem?

Instem's top insider investors include:
  1. David Gare (Insider)
  2. Nigel Goldsmith (Insider)
  3. Phil Reason (Insider)
“Move your money by early 2022,” Wall Street legend warns
A new form of technology will cause a massive shift in the wealth divide in 2022. Do you own the stocks that will be affected?
Details here…